ArticleThe Journal of infectious diseases2026
Adenovirus 40 and 41 Antibodies Associated With Protection From Infection in a Bangladeshi Birth Cohort.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAdenovirus (AdV) 40/41 is a major cause of pediatric acute gastroenteritis (AGE), leading to significant morbidity and mortality worldwide. As little is known about clinical correlates of protection, we analyzed AdV-specific antibody reactivities using a multi-AdV protein microarray and serum from a Bangladeshi birth cohort surveilled for diarrhea during the first 2 years of life.
methodsArrays contained a comprehensive set of proteins from AdV 40 and 41, in addition to respiratory AdVs 4, 5, and 26. Children were split into four groups according to AdV 40/41 infection occurrence during year 1 (Y1) and year 2 (Y2) of life. One-year array antibody reactivity levels were analyzed from 119 children using principal component analysis (PCA). Top antibody reactivities were evaluated for associations with AdV 40/41 disease severity and protection in Year 2 using logistic regression.
resultsEight principal components (PCs) were identified from PCA. Top targets contributing to the leading PCs included external AdV 40/41 antigens that function in host cell entry, particularly penton base (PB) proteins. AdV 41 PB antibody reactivity at Year 1 is significantly associated with reduced risk of AdV 40/41 infection in Year 2 (OR = 0.36, 95% CI: 0.16-0.80, P = .013, adjusted P = .003). Additionally, those with mild to moderate infections in Year 2 had higher reactivities to AdV 40 and 41 PB compared to severe infections (P = .008 and .032, respectively).
conclusionsHigher antibody reactivity to AdV PB was associated with improved Year 2 AdV 40/41 outcomes, elevating it as a promising vaccine or monoclonal antibody target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.